losartan-potassium and Lipodystrophy

losartan-potassium has been researched along with Lipodystrophy* in 2 studies

Other Studies

2 other study(ies) available for losartan-potassium and Lipodystrophy

Article	Year
Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. WMJ : official publication of the State Medical Society of Wisconsin, 2009, Volume: 108, Issue:9 Thiazolidinediones (TZDs) are frequently used pharmacotherapeutics for type II diabetes mellitus, which exert their effect through peroxisomal proliferator agonist receptor (PPAR) mediated increased insulin sensitivity. TZDs are known to cause marrow suppression and to stimulate adipogenesis. Case and cohort studies show TZDs worsen thyroid-associated orbitopathy. We present a case consistent with earlier reports of marrow suppressive pancytopenia manifesting as myelodysplastic syndrome, a new implication of hypoerythropoetinemia, and non-Graves'-associated proliferative proptosis. Topics: Diabetes Mellitus, Type 2; Erythropoietin; Exophthalmos; Female; Humans; Hypoglycemic Agents; Lipodystrophy; Middle Aged; Myelodysplastic Syndromes; Rosiglitazone; Thiazolidinediones	2009
The pregnant patient with partial lipodystrophy developing acute renal failure--onset of de novo membranoproliferative glomerulonephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1998, Volume: 13, Issue:8 Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Erythropoietin; Female; Glomerulonephritis, Membranoproliferative; Humans; Kidney; Lipodystrophy; Pregnancy; Pregnancy Complications; Renal Dialysis; Steroids	1998

Article

Year

Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.

WMJ : official publication of the State Medical Society of Wisconsin, 2009, Volume: 108, Issue:9

Thiazolidinediones (TZDs) are frequently used pharmacotherapeutics for type II diabetes mellitus, which exert their effect through peroxisomal proliferator agonist receptor (PPAR) mediated increased insulin sensitivity. TZDs are known to cause marrow suppression and to stimulate adipogenesis. Case and cohort studies show TZDs worsen thyroid-associated orbitopathy. We present a case consistent with earlier reports of marrow suppressive pancytopenia manifesting as myelodysplastic syndrome, a new implication of hypoerythropoetinemia, and non-Graves'-associated proliferative proptosis.

Topics: Diabetes Mellitus, Type 2; Erythropoietin; Exophthalmos; Female; Humans; Hypoglycemic Agents; Lipodystrophy; Middle Aged; Myelodysplastic Syndromes; Rosiglitazone; Thiazolidinediones

2009

The pregnant patient with partial lipodystrophy developing acute renal failure--onset of de novo membranoproliferative glomerulonephritis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1998, Volume: 13, Issue:8

Topics: Acute Kidney Injury; Adult; Anti-Inflammatory Agents; Erythropoietin; Female; Glomerulonephritis, Membranoproliferative; Humans; Kidney; Lipodystrophy; Pregnancy; Pregnancy Complications; Renal Dialysis; Steroids

1998